Acquisition Includes TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen 's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif. , Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and
SAN CARLOS, Calif. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022 . ChemoCentryx executive management will host a conference call and
-- Ms. Herron brings more than 25 years of therapeutics commercial experience and brand management to ChemoCentryx Board -- SAN CARLOS, Calif. , July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif.
SAN CARLOS, Calif. , May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS ® (avacopan), an orally administered selective complement 5a receptor (C5aR)
-- David E. Wheadon , M.D., Elected to the Board as an Independent Director -- -- Henry A. McKinnell , Jr., to Retire from Board -- SAN CARLOS, Calif. , May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced changes to the composition of its Board of Directors.
-- Supports plans to advance TAVNEOS ® (avacopan) into Phase III development for the treatment of patients with most severe form of hidradenitis suppurativa, Hurley Stage III -- SAN CARLOS, Calif. , May 18, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that a poster
SAN CARLOS, Calif. , May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 12:30 p.m. ET .
SAN CARLOS, Calif. , May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS ® (avacopan), an orally
-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global
